<DOC>
	<DOCNO>NCT01552499</DOCNO>
	<brief_summary>The purpose study determine whether EpiFix human amniotic membrane effective treatment diabetic foot ulcer .</brief_summary>
	<brief_title>Comparative Study Amniotic Membrane Wound Graft In Management Diabetic Foot Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>Male female age 18 old Informed consent must obtain Patient 's ulcer must diabetic origin large 1cm2 . Debridement do prior randomization . Subject 's informed consent participate study , must obtain prior proceed sharp debridement . Patients Type 1 Type 2 diabetes ( criterion diagnosis diabetes mellitus per ADA ) . Ulcer must present minimum four week direction , documented failure prior treatment heal wound . Patient 's ulcer must exhibit clinical sign infection . Patient legal consenting age . Patient willing provide inform consent willing participate procedure follow evaluation necessary complete study . Serum Creatine le 3.0mg/dl HbA1c less 12 % Patient adequate circulation affect extremity , demonstrate one follow within past 60 day : Dorsum transcutaneous oxygen test ( TcPO2 ) result ≥30mmHg , OR ABIs result ≥0.7 ≤1.2 , OR Doppler arterial waveform , triphasic biphasic ankle affect leg Patients present ulcer probe bone ( UT Grade IIIAD ) . A positive probetobone confirm bone joint felt sterile , ophthalmological probe . Patients whose index diabetic foot ulcer great 25cm2 . Patients consider reasonable metabolic control , confirm HbA1c great 12 % within previous 90 day , Patients whose serum creatinine level 3.0mg/dl great . Patients known history poor compliance medical treatment . Patients previously randomize study , presently participate another clinical trial . Patients currently receive radiation therapy chemotherapy . Patients know suspected local skin malignancy index diabetic ulcer . Patients anticoagulant medication surgical procedure , monitor accord protocol employ enrol center . Patients diagnose autoimmune connective tissue disease . Nonrevascularizable surgical site . Active infection site . Any pathology would limit blood supply compromise healing . Patients receive biomedical topical growth factor wound within previous 30 day . Patient pregnant breast feeding . Patient take medication consider immune system modulator could affect graft incorporation . Allergy Gentamycin Streptomycin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>